Send to

Choose Destination
See comment in PubMed Commons below
Can J Urol. 2006 Dec;13(6):3317-20.

Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.

Author information

Upstate Medical University, Department of Urology, Syracuse, New York 13210, USA.


Bladder cancer is the fifth most common cancer in the Western world and is on the rise. Most patients present with superficial disease and are treated by transurethral resection of bladder tumor. More than half of these patients experience recurrence with about 20% progressing to muscle invasive disease. Intravesical chemotherapy has been shown to decrease the risk of recurrence of bladder cancer. Mitomycin C has emerged as a major agent for an immediate post-resection intravesical instillation. This article reviews the literature on the mode of action, rationale for immediate adjuvant treatment with Mitomycin C and adverse effects associated with its use.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center